Abstract
Nivolumab is one of the immune checkpoint inhibitors available for chemotherapy-resistant gastric cancer. There have been few reports of confirmed prominent shrinkage of the primary tumor and some reports of prolonged antitumor effect after discontinuance of the drug, but it is not universal. A 67-year-old male was admitted to our hospital and diagnosed with metastatic gastric cancer that had spread to the bilateral lobe of the liver, distant lymph nodes, and peritoneum. He received five courses of S-1 plus oxaliplatin, followed by three courses of ramucirumab plus paclitaxel leading to disease progression. Then, the patient was administered nivolumab as third-line therapy. Tumor size was markedly reduced after three courses, esophagogastroduodenoscopy (EGD) revealed scar formation on the lower gastric corpus after seven courses, and biopsy specimen showed no malignancy. When a slight lower limb muscle weakness manifested, possibly an immune-related adverse event (irAE) after 15 courses, we stopped administration of nivolumab. The patient has survived for 26 months since his first visit, and elimination of the primary tumor and ascites with noted shrinkage of liver and lymph node metastases have followed for more than 10 months since discontinuance of nivolumab.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kang YK, Boku N, Satoh T et al (2017) Nivolumab in patients with advance gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet 390:2461–2471
Chen LT, Satoh T, Ryu MH et al (2019) A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. Gastric Cancer (in press). https://doi.org/10.1007/s10120-019-01034-7
Gettinger S, Horn L, Jackman D et al (2018) Five-year following-up of nivolumab in previously treated advanced non-small-cell lung cancer. J Clin Oncol 36:1675–1684
Topalian SL, Sznol M, McDermott DF et al (2014) Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32:1020–1030
Namikawa T, Ishida N, Tsuda S et al (2018) Successful treatment of liver metastases arising from early gastric cancer achieved clinical complete response by nivolumab. Surg Case Rep 4:71
Kashima S, Tanabe H, Tanino M et al (2019) Lymph node metastasis from gastroesophageal cancer successfully treated by nivolumab: a case report of a young patient. Front Oncol 9:1375
Cancer Genome Atlas Reserch Network (2014) Comprehensive moleculer characterizeation of gastric adenocarcinoma. Nature 513(7517):202–209
Teng MW, Ngiow SF, Ribas A et al (2015) Classifying cancers based on T cell infiltrateon and PD-L1. Cancer Res 75(11):2139–2145
Gajewski TF, Schreiber H, Fu YX (2013) Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 14(10):1014–1022
Kim ST, Cristescu R, Bass AJ et al (2018) Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med 24(9):1449–1458
Osa A, Uenami T, Koyama S et al (2018) Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients. JCI Insight 3:e59125
Spigel DR, McLeod M, Hussein MA et al (2017) Randomized results of fixed-duration (1-yr) vs continuous nivolumab in patients (pts) with advanced non-small cell lung cancer (NSCLC). Ann Oncol 28:v460–v496
Santini FC, Rizvi H, Plodkowski AJ et al (2018) Safety and efficacy of re-treating with immunotherapy after immune-related adverse events in patients with NSCLC. Cancer Immunol Res 6:1093–1099
Shiono A, Kaira K, Mouri A et al (2019) Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non-small cell lung cancer patients. Thorac Cancer 10:775–781
Suzuki S, Toyoma S, Tomizawa H et al (2019) Efficacy of chemotherapy after progression with nivolumab in squamous cell carcinoma of the head and neck. Auris Nasus Larynx (in press). https://doi.org/10.1016/j.anl.2019.06.004
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no competing interests.
Informed consent
Informed consent was obtained from the patient in this report.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Doi, H., Ninomiya, M., Toyota, K. et al. A case of multiple metastatic gastric cancer with primary lesion vanished after administrating nivolumab, and the effect remains even after discontinuance of therapy. Int Canc Conf J 9, 187–192 (2020). https://doi.org/10.1007/s13691-020-00432-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13691-020-00432-4